{"id":"tafamidis-reference","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inducers (e.g., rifampin, phenytoin)","action":"Avoid","effect":"Decreased tafamidis exposure"},{"drug":"P-glycoprotein inhibitors (e.g., verapamil, quinidine)","action":"Monitor","effect":"Increased tafamidis exposure"}],"contraindications":["Hypersensitivity to tafamidis or any component of the formulation; Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, have been reported."]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_fixedAt":"2026-03-30T11:35:55.943123","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tafamidis-reference","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:56:35.162310+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:56:44.009298+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:56:35.180976+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tafamidis-reference","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:56:44.788547+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Transthyretin stabiliser","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:56:45.580265+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103837/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:56:45.487510+00:00"}},"allNames":"tafamidis (reference)","offLabel":[],"timeline":[],"brandName":"Tafamidis (Reference)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"TTR protein","novelty":"first-in-class","modality":"small molecule","drugClass":"Stabilizer","explanation":"","oneSentence":"","technicalDetail":"Tafamidis binds to the TTR protein at the thyroxine-binding site, stabilizing its native tetrameric structure and preventing misfolding and aggregation. This action reduces the formation of amyloid fibrils and slows disease progression. Tafamidis has been shown to be effective in slowing the progression of FAP in clinical trials."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=tafamidis-reference","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tafamidis-reference","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:56:47.371087+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Vyndaqel","company":"Pfizer","advantage":"Longer duration of action compared to Tafamidis","genericName":"tafamidis"},{"name":"Vyndamax","company":"Pfizer","advantage":"Once-daily dosing compared to Tafamidis","genericName":"tafamidis"},{"name":"Patisiran","company":"Ionis Pharmaceuticals","advantage":"Targeting the underlying cause of transthyretin amyloidosis","genericName":"patisiran"}],"genericName":"tafamidis-reference","indications":{"approved":[{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"},{"name":"Chronic Familial Amyloid Polyneuropathy (hATTR) in adults with a family history of the disease","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_fixedFields":["trials(5)"],"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07470866","phase":"PHASE1","title":"A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-03-27","conditions":"Healthy","enrollment":24},{"nctId":"NCT06705569","phase":"PHASE1","title":"A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-12-20","conditions":"Healthy","enrollment":22},{"nctId":"NCT06273839","phase":"PHASE1","title":"A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-02-27","conditions":"Healthy","enrollment":12},{"nctId":"NCT05498701","phase":"PHASE1","title":"A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-29","conditions":"Healthy","enrollment":22},{"nctId":"NCT05482308","phase":"PHASE1","title":"A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-29","conditions":"Healthy","enrollment":12}],"_emaApprovals":[{"date":"","name":"Tafamidis (Reference)","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL2103837","moleculeType":"Small molecule","molecularWeight":"308.12"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2103837"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:56:47.371087+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}